SHANDONG XINHUA (00719) announced that its wholly-owned subsidiary, Shandong Zibo Xinda Pharmaceutical Co., Ltd., recently received the Drug Registration Certificate for Saxagliptin and Metformin Extended-Release Tablets (I) and (III) issued by the National Medical Products Administration. The product, used in conjunction with diet and exercise, is suitable for adult patients with type 2 diabetes who require treatment with saxagliptin and metformin to improve glycemic control. It is not indicated for patients with type 1 diabetes or diabetic ketoacidosis. The product is listed as a Category B drug in the National Reimbursement Drug List (2025). According to relevant statistics, sales of saxagliptin and metformin extended-release tablets in China's public medical institutions reached approximately RMB 419 million in 2024. The recent approval of Xinda Pharmaceutical's Saxagliptin and Metformin Extended-Release Tablets (I) and (III) will help enrich the company's portfolio of diabetes treatments and enhance its overall competitiveness.